DDInter1927 DDInter927
Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Venlafaxine {u} (Compound) resembles {v} (Compound) Tramadol
Venlafaxine {u} (Compound) resembles {v} (Compound) Desvenlafaxine
Venlafaxine {u} (Compound) binds {v} (Gene) NPY1R
Venlafaxine {u} (Compound) palliates {v} (Disease) panic disorder
Venlafaxine {u} (Compound) is included by {v} (Pharmacologic Class) Norepinephrine Uptake Inhibitors
Venlafaxine {u} (Compound) causes {v} (Side Effect) Yawning
Venlafaxine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lenvatinib
Venlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Venlafaxine {u} may lead to a major life threatening interaction when taken with {v} Procarbazine
Venlafaxine (Compound) resembles Tramadol (Compound)
Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Venlafaxine (Compound) binds NPY1R (Gene)
Venlafaxine (Compound) palliates panic disorder (Disease)
Venlafaxine (Compound) is included by Norepinephrine Uptake Inhibitors (Pharmacologic Class)
Venlafaxine (Compound) causes Yawning (Side Effect)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Venlafaxine may lead to a major life threatening interaction when taken with Procarbazine